Over-activation of TGF-b signaling is observed in myelodysplastic syndromes and is associated with dysplastic hematopoietic differentiation. Galunisertib, a first-in-class oral inhibitor of the TGF-b receptor type 1 kinase (ALK5) has shown effectiveness in preclinical models of myelodysplastic syndromes (MDS) and acceptable toxicity in phase 1 studies of solid malignancies.
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes / Santini, Valeria; Valcárcel, David; Platzbecker, Uwe; Komrokji, Rami S; Cleverly, Ann; Lahn, Michael M; Janssen, Jan; Zhao, Yumin; Chiang, Alan; Giagounidis, Aristoteles; Guba, Susan C; Sridharan, Ashwin; Gueorguieva, Ivelina; Girvan, Alicia; da Silva Ferreira, Mariana; Bhagat, Tushar D; Pradhan, Kith; Steidl, Ulrich; Will, Britta; Verma, Amit. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - STAMPA. - 25:(2019), pp. 6976-6985. [10.1158/1078-0432.CCR-19-1338]
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Santini, Valeria
;
2019
Abstract
Over-activation of TGF-b signaling is observed in myelodysplastic syndromes and is associated with dysplastic hematopoietic differentiation. Galunisertib, a first-in-class oral inhibitor of the TGF-b receptor type 1 kinase (ALK5) has shown effectiveness in preclinical models of myelodysplastic syndromes (MDS) and acceptable toxicity in phase 1 studies of solid malignancies.
| File | Dimensione | Formato | |
|---|---|---|---|
|
6976.full_ALK5.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
569.26 kB
Formato
Adobe PDF
|
569.26 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
